Post by xray on Aug 9, 2021 20:26:35 GMT
There are a few CEF's on my "Watch List" doing extremely well and all of them are 10star rated [for aT LEAST 3-weeks now] with report card grades of 92 thru 100. Something to put on your current watch list [IMHO]:
CEF .. Star rating .. 13wk Star Rating .. Report Card Grade .. Power Rating .. Rf [Risk w/2%Portfolio] .. Dividend% .. Discount .. NAVChg 12/31 to date
GPM.... 10star ....... 9.50 Stars .......................... 95 ..................... 100 ........................ +0.436 ...................... 5.22% ...+1.07 Pos ..............+1.52
HQH.... 10star ....... 9.17 Stars .......................... 92 ..................... 100 ........................ +0.519 ...................... 7.46% ...+1.01 Pos ..............+2.19
HQL.... 10star ....... 9.50 Stars .......................... 95 ..................... 100 ........................ +0.498 ...................... 5.69% ...+1.06 Pos ..............+1.58
LGI..... 10star ....... 10.0 Stars ......................... 100 .................... 100 ........................ +0.336 ...................... 6.52% ...+1.03 Pos ..............+2.44
Additional Comments:
GPM was thought to be folded into GOF [currently at a substantial "Premium"] in the 3rd Qtr [?] ... No interest at this time ...
HQH is a Health CEF that normally is within the MktPrc range of 19-24 ... Distribution announcement approx 8/18 ... 8% div policy ...
Tekla Healthcare Investors Announce Renewal of Share Repurchase Program
March 25, 2021
Tekla Healthcare Investors (the "Fund") announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2021. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2022. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund’s shares and the net asset value per share. The share repurchase program is intended to increase the Fund’s net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.
The amount and timing of repurchases will be at the discretion of Tekla Capital Management LLC, the investment adviser to the Fund. There is no assurance that the Fund will purchase shares at any specific discount levels or in any specific amounts or on any specific date. The Fund’s repurchase activity will be disclosed in its shareholder report for the relevant fiscal period. There is no assurance that the market price of the Fund’s shares, either absolute or relative to net asset value, will increase as a result of any share repurchases. The Board will monitor the effect of the share repurchase program on the Fund’s market prices and net asset value per share, expense ratio and investment strategy over time.
HQL is a Health CEF that normally is within the MktPrc range of 18-22 ... Distribution announcement approx 8/18 ... 8% div policy ...
Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program
March 25, 2021
Tekla Life Sciences Investors (the "Fund") announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2021. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year-period ending July 14, 2022. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund’s shares and the net asset value per share. The share repurchase program is intended to increase the Fund’s net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.
The amount and timing of repurchases will be at the discretion of Tekla Capital Management LLC, the investment adviser to the Fund. There is no assurance that the Fund will purchase shares at any specific discount levels or in any specific amounts or on any specific date.
LGI is a Global Tttl Return CEF that normally is within the MktPrc range of 16-21 ... Div Announcement Monthly ... 7% div policy .. x-div 8-10 ...
Lazard Global Total Return and Income Fund Confirms New Distribution
January 4, 2021
Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its level distribution policy, as previously authorized by its Board of Directors, a monthly distribution of $0.11512, equivalent to 7.0% (annualized) of the Fund’s net asset value per share as of the close of markets on December 31, 2020 on the Fund’s outstanding common stock. The distribution is payable on January 22, 2021 to shareholders of record on January 11, 2021. The ex-dividend date is January 8, 2021.
The Fund’s investment objective is total return, consisting of capital appreciation and current income. The Fund’s net assets are invested in a portfolio of approximately 60 to 80 US and non-US equity securities, including American Depository Receipts, generally of companies with market capitalizations greater than $2 billion, and may include investments in emerging markets. The Fund also invests in emerging market currencies (primarily by entry into forward currency contracts), or instruments whose value is derived from the performance of an underlying emerging market currency, and also may invest in debt obligations, including government, government agency and corporate obligations and structured notes denominated in emerging market currencies.
Insider Activity:
GPM ... None
HQH ... 5,000sh @ 20.68 on 10/26/20
HQL ... 16,000sh @ 17.52 on 10/26/20
LGI .... None
Disclosure: Some of us currently not have any positions in any of the above since our "Goals and Objectives" involve a 10% [minimum] dividend being paid yearly with a 5% CapGain [projection]. Should the market take a major correction, a re-analysis will be made to move them up to current portfolio....
Live Long and Prosper....
CEF .. Star rating .. 13wk Star Rating .. Report Card Grade .. Power Rating .. Rf [Risk w/2%Portfolio] .. Dividend% .. Discount .. NAVChg 12/31 to date
GPM.... 10star ....... 9.50 Stars .......................... 95 ..................... 100 ........................ +0.436 ...................... 5.22% ...+1.07 Pos ..............+1.52
HQH.... 10star ....... 9.17 Stars .......................... 92 ..................... 100 ........................ +0.519 ...................... 7.46% ...+1.01 Pos ..............+2.19
HQL.... 10star ....... 9.50 Stars .......................... 95 ..................... 100 ........................ +0.498 ...................... 5.69% ...+1.06 Pos ..............+1.58
LGI..... 10star ....... 10.0 Stars ......................... 100 .................... 100 ........................ +0.336 ...................... 6.52% ...+1.03 Pos ..............+2.44
Additional Comments:
GPM was thought to be folded into GOF [currently at a substantial "Premium"] in the 3rd Qtr [?] ... No interest at this time ...
HQH is a Health CEF that normally is within the MktPrc range of 19-24 ... Distribution announcement approx 8/18 ... 8% div policy ...
Tekla Healthcare Investors Announce Renewal of Share Repurchase Program
March 25, 2021
Tekla Healthcare Investors (the "Fund") announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2021. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2022. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund’s shares and the net asset value per share. The share repurchase program is intended to increase the Fund’s net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.
The amount and timing of repurchases will be at the discretion of Tekla Capital Management LLC, the investment adviser to the Fund. There is no assurance that the Fund will purchase shares at any specific discount levels or in any specific amounts or on any specific date. The Fund’s repurchase activity will be disclosed in its shareholder report for the relevant fiscal period. There is no assurance that the market price of the Fund’s shares, either absolute or relative to net asset value, will increase as a result of any share repurchases. The Board will monitor the effect of the share repurchase program on the Fund’s market prices and net asset value per share, expense ratio and investment strategy over time.
HQL is a Health CEF that normally is within the MktPrc range of 18-22 ... Distribution announcement approx 8/18 ... 8% div policy ...
Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program
March 25, 2021
Tekla Life Sciences Investors (the "Fund") announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2021. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year-period ending July 14, 2022. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund’s shares and the net asset value per share. The share repurchase program is intended to increase the Fund’s net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.
The amount and timing of repurchases will be at the discretion of Tekla Capital Management LLC, the investment adviser to the Fund. There is no assurance that the Fund will purchase shares at any specific discount levels or in any specific amounts or on any specific date.
LGI is a Global Tttl Return CEF that normally is within the MktPrc range of 16-21 ... Div Announcement Monthly ... 7% div policy .. x-div 8-10 ...
Lazard Global Total Return and Income Fund Confirms New Distribution
January 4, 2021
Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its level distribution policy, as previously authorized by its Board of Directors, a monthly distribution of $0.11512, equivalent to 7.0% (annualized) of the Fund’s net asset value per share as of the close of markets on December 31, 2020 on the Fund’s outstanding common stock. The distribution is payable on January 22, 2021 to shareholders of record on January 11, 2021. The ex-dividend date is January 8, 2021.
The Fund’s investment objective is total return, consisting of capital appreciation and current income. The Fund’s net assets are invested in a portfolio of approximately 60 to 80 US and non-US equity securities, including American Depository Receipts, generally of companies with market capitalizations greater than $2 billion, and may include investments in emerging markets. The Fund also invests in emerging market currencies (primarily by entry into forward currency contracts), or instruments whose value is derived from the performance of an underlying emerging market currency, and also may invest in debt obligations, including government, government agency and corporate obligations and structured notes denominated in emerging market currencies.
Insider Activity:
GPM ... None
HQH ... 5,000sh @ 20.68 on 10/26/20
HQL ... 16,000sh @ 17.52 on 10/26/20
LGI .... None
Disclosure: Some of us currently not have any positions in any of the above since our "Goals and Objectives" involve a 10% [minimum] dividend being paid yearly with a 5% CapGain [projection]. Should the market take a major correction, a re-analysis will be made to move them up to current portfolio....
Live Long and Prosper....